1. Home
  2. MWH vs DFTX Comparison

MWH vs DFTX Comparison

Compare MWH & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOLV Energy Inc. Class A Common Stock

MWH

SOLV Energy Inc. Class A Common Stock

N/A

Current Price

$25.32

Market Cap

4.9B

Sector

Industrials

ML Signal

N/A

Logo Definium Therapeutics Inc. Common Shares

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$38.13

Market Cap

5.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MWH
DFTX
Founded
2008
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
5.9B
IPO Year
2026
2020

Fundamental Metrics

Financial Performance
Metric
MWH
DFTX
Price
$25.32
$38.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
8
Target Price
$35.42
$38.50
AVG Volume (30 Days)
1.8M
2.1M
Earning Date
03-19-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.11
N/A
Revenue
N/A
N/A
Revenue This Year
$51.86
N/A
Revenue Next Year
$14.78
N/A
P/E Ratio
$227.09
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.83
$14.62
52 Week High
$48.40
$49.70

Technical Indicators

Market Signals
Indicator
MWH
DFTX
Relative Strength Index (RSI) 36.12 37.04
Support Level $23.83 $16.37
Resistance Level $30.74 $49.13
Average True Range (ATR) 1.45 2.13
MACD -0.49 -0.88
Stochastic Oscillator 12.00 8.32

Price Performance

Historical Comparison
MWH
DFTX

About MWH SOLV Energy Inc. Class A Common Stock

SOLV Energy Inc is a provider of infrastructure services to the power industry, including engineering, procurement, construction, testing, commissioning, operations, maintenance and repowering. It specializes in designing, building and maintaining utility-scale solar and battery storage projects and related T&D infrastructure. The company's projects include: The Eldorado Solar Project, Gravel Pit Solar Project, and Vikings Solar-plus-Storage Project. It operates in one reportable segment which derives revenue through providing EPC, O&M and Development services throughout the Unites Sates. The company derives maximum of revenue from its EPC contracts.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Share on Social Networks: